Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome Holdings, Inc. (HIND)
Company Research
Source: Business Wire
Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billionModeled peak annual U.S. sales approaching USD 600 million for VT-1953Independent valuation analysis estimates post-Phase 3 asset value approaching USD 1 billion, and the current valuation with a positive Phase 2 is estimated to be USD 455 million CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis commissioned by Vyome and conducted by Destum Partners, Inc. (“Destum Partners”), a reputed life sciences strategy and transaction advisory firm.The independent analysis evaluated VT-1953, Vyome’s lead clinical candidate for the treatment of symptoms of malignant fungating wounds (MFW), a rare and devastating complicati
Show less
Read more
Impact Snapshot
Event Time:
HIND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIND alerts
High impacting Vyome Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
HIND
News
- Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 MonthsBusiness Wire
- Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 ResultsBusiness Wire
- Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
HIND
Sec Filings
- 1/28/26 - Form 8-K
- 12/23/25 - Form 8-K
- 11/26/25 - Form 424B3
- HIND's page on the SEC website